Modulating the Immune System
Our proprietary, T-cell Activation Platform (TCAP) produces therapies designed to turn “cold” tumors “hot,” and to be administered in combination with checkpoint inhibitors as well as other immuno-modulators to increase their effectiveness.
Our TechnologiesRobust Pipeline of Drugs to Activate the Body’s Own T-cells
Our proprietary, T-cell Activation Platform (TCAP) can be administered in combination with checkpoint inhibitors and other immuno-modulators. We are currently enrolling patients in our Phase 2 clinical trial for non-small cell lung cancer, in combination with checkpoint inhibitors and plan to enter the clinic soon with our ComPACT and PTX-35 programs.
Our Product Pipeline